AriBio’s once-daily Alzheimer’s pill, AR1001, has demonstrated its potential to slow clinical decline by 31% within a specific patient population with early disease, as the field seeks out therapies that can modify the course of this neurodegenerative condition. 

This win stems from the Phase III POLARIS-AD study (NCT05531526), in which AriBio pitted AR1001, a phosphodiesterase-5 (PDE5) inhibitor, against placebo in patients with early Alzheimer’s disease. Some patients received AR1001 as a monotherapy, while others were taking symptomatic drugs such as memantine or an acetylcholinesterase inhibitor at the beginning of the trial. 

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As per topline results first presented at the 2026 Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego, taking place from 16 to 19 November, AR1001 met the trial’s primary endpoint in the prespecified monotherapy population, with patients achieving a 0.44-point reduction in their clinical dementia rating sum of boxes (CDR-SB) scores – equating to a 31% slowing of clinical decline. 

However, researchers did not observe this significant effect on CDR-SB scores – a common clinical measure of disease severity in Alzheimer’s – within the overall study population, as the treatment difference stood at -0.11 points, suggesting lower benefit from the drug directly when used in combination. Nonetheless, the data did numerically favour AR1001 over placebo. 

On top of this, AR1001 triggered a numerically favourable, but not statistically significant, 1.16-point reduction over placebo on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog 13). Patients given the PDE5 inhibitor also experienced a 0.7-point improvement in scores obtained during the mini mental state examination (MMSE) over placebo. 

On the tolerability side, most of the adverse events (AEs) experienced by patients following treatment with AR1001 were mild-to-moderate. However, four patients treated with the drug endured fatal AEs versus two in the placebo group, and 5.2% of patients discontinued treatment with AR1001 due to an AE. 

According to Richard Oakley, associate director for research and innovation at the Alzheimer’s Society, the POLARIS-AD results represent an “exciting sign” that a new cause-addressing treatment for Alzheimer’s disease could be on the horizon. 

“Over the year of the trial, this drug was able to effectively slow down people’s decline in memory and thinking by nearly a third, and the side effects reported were mostly mild to moderate,” Oakley commented.  

“However, the drug doesn’t seem to be as effective for people taking other drugs for Alzheimer’s symptoms, so this needs further investigation,” he added. 

Meanwhile, POLARIS-AD global principal investigator, Sharon Sha, noted that the secondary endpoints and biomarker findings “warrant further evaluation alongside the overall population outcome,” which would help further inform what therapeutic potential AR1001 can have in Alzheimer’s disease. 

“The work of POLARIS-AD is another step towards filling an unmet need in early Alzheimer’s disease in which patients need more options for treatment,” Sha said. 

If AR1001 were to secure regulatory approval, it would become the first medicine in its class to reach the Alzheimer’s disease market and would build on the disease-modifying legacy built by anti-amyloid drugs like Eli Lilly’s Kisunla (donanemab) and Biogen and Eisai’s Leqembi (lecanemab). Unlike these medicines, which focus on clearing harmful protein plaques in the brain, AR1001 acts in a similar way to Viagra by relaxing blood vessels – enhancing blood flow to the brain. 

With topline, late-stage results in the bag, AriBio will look to the complete findings of POLARIS-AD, which the South Korean biotech plans to share with the US Food and Drug Administration (FDA) to inform next steps.